Cadence Pharmaceuticals PT Raised to $15.00 at Wedbush (CADX)
Research analysts at Wedbush hoisted their price objective on shares of Cadence Pharmaceuticals (NASDAQ:CADX) from $12.00 to $15.00 in a report released on Friday, American Banking News.com reports. Wedbush’s target price would suggest a potential upside of 27.66% from the stock’s previous close.
Cadence Pharmaceuticals (NASDAQ:CADX) traded up 0.09% during mid-day trading on Friday, hitting $11.76. 410,065 shares of the company’s stock traded hands. Cadence Pharmaceuticals has a one year low of $4.45 and a one year high of $11.92. The stock’s 50-day moving average is $9.59 and its 200-day moving average is $7.06. The company’s market cap is $1.012 billion.
A number of other analysts have also recently weighed in on CADX. Analysts at Guggenheim raised their price target on shares of Cadence Pharmaceuticals from $9.00 to $15.00 in a research note to investors on Tuesday, December 3rd. They now have a “buy” rating on the stock. Analysts at Pacific Crest upgraded shares of Cadence Pharmaceuticals to an “outperform” rating in a research note to investors on Tuesday, November 26th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $9.91.
Cadence Pharmaceuticals, Inc operates as a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics utilized primarily in the hospital setting.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.